KFC
REGN icon

Klingenstein Fields & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Klingenstein Fields & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$466K Sell
747
-14,819
-95% -$10.1M 0.02% 139
2026
Q1 		$12M Sell
15,566
-369
-2% -$283K 0.47% 55
2025
Q4 		$12.3M Sell
15,935
-138
-0.9% -$93.7K 0.46% 55
2025
Q3 		$9.04M Sell
16,073
-26
-0.2% -$14.7K 0.34% 65
2025
Q2 		$8.45M Buy
16,099
+9,155
+132% +$5.11M 0.33% 66
2025
Q1 		$4.4M Buy
6,944
+138
+2% +$94.9K 0.19% 73
2024
Q4 		$4.85M Buy
6,806
+6,231
+1,084% +$5.23M 0.2% 73
2024
Q3 		$604K Hold
575
– – 0.02% 114
2024
Q2 		$604K Hold
575
– – 0.03% 112
2024
Q1 		$553K Hold
575
– – 0.02% 114
2023
Q4 		$505K Sell
575
-1
-0.2% -$823 0.02% 116
2023
Q3 		$474K Hold
576
– – 0.02% 116
2023
Q2 		$414K Buy
576
+1
+0.2% +$771 0.02% 118
2023
Q1 		$472K Hold
575
– – 0.02% 111
2022
Q4 		$415K Hold
575
– – 0.02% 126
2022
Q3 		$396K Hold
575
– – 0.02% 130
2022
Q2 		$340K Hold
575
– – 0.02% 134
2022
Q1 		$402K Sell
575
-225
-28% -$142K 0.02% 140
2021
Q4 		$505K Sell
800
-85
-10% -$52.3K 0.02% 131
2021
Q3 		$536K Hold
885
– – 0.02% 134
2021
Q2 		$494K Hold
885
– – 0.02% 141
2021
Q1 		$419K Buy
885
+375
+74% +$183K 0.02% 142
2020
Q4 		$246K Buy
+510
New +$275K 0.01% 162
2017
Q2 		– Sell
-1,940
Closed -$752K – 227
2017
Q1 		$752K Buy
1,940
+40
+2% +$14.8K 0.03% 140
2016
Q4 		$697K Buy
+1,900
New +$723K 0.03% 144

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Klingenstein Fields & Co's REGN Position: Q2 2026 in Review

Klingenstein Fields & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 95% in Q2 2026, selling an estimated $10.1M and leaving 747 shares worth $466K. The position accounts for 0.02% of the portfolio, ranked #139.

Klingenstein Fields & Co first reported a position in REGN in Q4 2016 and has held it in 25 quarters since. The position peaked at $12.3M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Klingenstein Fields & Co held 747 shares of Regeneron Pharmaceuticals worth $466K as of Q2 2026.
  • Klingenstein Fields & Co sold 14,819 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $10.1M.
  • Regeneron Pharmaceuticals made up 0.02% of Klingenstein Fields & Co's portfolio in Q2 2026, its #139 holding.
  • Klingenstein Fields & Co first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 25 quarters since.
  • Klingenstein Fields & Co's Regeneron Pharmaceuticals position peaked at $12.3M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Klingenstein Fields & Co's 13F filing for Q2 2026, filed 5 Aug 2026.